Compounds > cabergoline
Page last updated: 2024-08-23

cabergoline and Acromegaly Due To Pituitary Adenoma

cabergoline has been researched along with Acromegaly Due To Pituitary Adenoma in 17 studies

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (17.65)29.6817
2010's10 (58.82)24.3611
2020's4 (23.53)2.80

Authors

AuthorsStudies
Auriemma, RS; Colao, A; Negri, M; Patalano, R; Pirchio, R; Pivonello, C; Pivonello, R1
Okayama, A; Sato, T; Shimatsu, A; Yamaguchi, H1
Kawakami, K; Matsubayashi, K1
Abreu, C; Cadena-Obando, D; Cuevas-Ramos, D; Espinosa-de-Los-Monteros, AL; González-Virla, B; Ibarra-Salce, R; Mercado, M; Mercado-Cherem, A; Pérez-Reyes, SP; Portocarrero-Ortiz, LA; Sosa-Eroza, E; Talavera, JO; Vergara-López, A1
Agostini, H; Arnoux, A; Brailly-Tabard, S; Chanson, P; Kuhn, E; Massart, C; Mavromati, M; Piketty, ML; Souberbielle, JC; Young, J1
Cha, HJ; Kim, JH; Kim, SW; Kim, YH; Lee, JH; Lee, SY; Paek, SH; Shin, CS1
Arnez, L; Biagetti, B; Dalama, B; Mesa, J; Obiols, G; Valladares, S1
Aller, J; Alvarez-Escolá, C; Bernabeu, I; Biagetti, B; Blanco, C; Cámara, R; Castells, I; Fajardo, C; García, R; Gaztambide, S; Mora, M; Picó, A; Pozo, CD; Resmini, E; Salinas, I; Sesmilo, G; Soto, A; Torres, E; Villabona, C; Webb, SM1
Marek, J1
Bronstein, MD; Fleseriu, M; Greenman, Y; Jallad, RS; Shimon, I; Yedinak, CG1
Albuquerque, JL; Azevedo, MF; Casulari, LA; Faria, MS; Figueiredo, P; Montenegro, RM; Nascimento, GC; Naves, LA; Vilar, L1
Chanson, P; Maison, P; Sandret, L1
Díez, JJ; Iglesias, P1
Fukuoka, H; Iguchi, G; Inoshita, N; Nishizawa, H; Suda, K; Takahashi, M; Takahashi, Y; Yamada, S; Yamamoto, M1
Colao, A; Di Somma, C; Lombardi, G; Pivonello, R; Savastano, S; Tauchmanovà, L1
Barlier, A; Brue, T; Jaquet, P; Saveanu, A1
Barlier, A; Culler, MD; Dufour, H; Fusco, A; Germanetti, AL; Gunz, G; Jaquet, P; Saveanu, A1

Reviews

4 review(s) available for cabergoline and Acromegaly Due To Pituitary Adenoma

ArticleYear
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aminoquinolines; beta-Arrestins; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Filamins; Growth Hormone-Secreting Pituitary Adenoma; Humans; Lisuride; MicroRNAs; Pergolide; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2

2021
Place of cabergoline in acromegaly: a meta-analysis.
    The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:5

    Topics: Acromegaly; Adult; Antineoplastic Agents; Cabergoline; Data Interpretation, Statistical; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Hormone Antagonists; Human Growth Hormone; Humans; Hyperprolactinemia; Insulin-Like Growth Factor I; Male; Middle Aged; Somatostatin; Treatment Outcome

2011
[Optimization of the medical treatment for acromegaly].
    Medicina clinica, 2013, Apr-20, Volume: 140, Issue:8

    Topics: Acromegaly; Cabergoline; Combined Modality Therapy; Dopamine Agonists; Dosage Forms; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ergolines; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Randomized Controlled Trials as Topic; Receptors, Somatotropin; Somatostatin; Treatment Outcome

2013
Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
    Molecular and cellular endocrinology, 2008, May-14, Volume: 286, Issue:1-2

    Topics: Adenoma; Antineoplastic Agents, Hormonal; Cabergoline; Cell Proliferation; Dopamine; Ergolines; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Octreotide; Pituitary Neoplasms; Protein Multimerization; Receptors, Dopamine D2; Receptors, Somatostatin; Somatostatin; Tumor Cells, Cultured

2008

Other Studies

13 other study(ies) available for cabergoline and Acromegaly Due To Pituitary Adenoma

ArticleYear
Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
    Endocrine journal, 2020, Feb-28, Volume: 67, Issue:2

    Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Chemical and Drug Induced Liver Injury; Child; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hypoglycemia; Insulin-Like Growth Factor I; Japan; Male; Middle Aged; Neurosurgical Procedures; Octreotide; Peptides, Cyclic; Product Surveillance, Postmarketing; Radiotherapy; Receptors, Somatotropin; Somatostatin; Tumor Burden; Young Adult

2020
Prevalence, incidence, comorbidities, and treatment patterns among Japanese patients with acromegaly: a descriptive study using a nationwide claims database.
    Endocrine journal, 2020, Oct-28, Volume: 67, Issue:10

    Topics: Acromegaly; Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Comorbidity; Dopamine Agonists; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hyperlipidemias; Hypertension; Incidence; Japan; Male; Middle Aged; Neurosurgical Procedures; Octreotide; Peptides, Cyclic; Prevalence; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Somatostatin; Young Adult

2020
Surgical and Pharmacological Outcomes in Acromegaly: Real-Life Data From the Mexican Acromegaly Registry.
    The Journal of clinical endocrinology and metabolism, 2020, 12-01, Volume: 105, Issue:12

    Topics: Acromegaly; Adenoma; Adult; Cabergoline; Combined Modality Therapy; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Mexico; Middle Aged; Neurosurgical Procedures; Postoperative Period; Prognosis; Registries; Retrospective Studies; Somatostatin; Treatment Outcome

2020
Classification of Patients With GH Disorders May Vary According to the IGF-I Assay.
    The Journal of clinical endocrinology and metabolism, 2017, 08-01, Volume: 102, Issue:8

    Topics: Acromegaly; Adenoma; Adult; Aged; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Drug Therapy, Combination; Dwarfism, Pituitary; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Immunoassay; Insulin-Like Growth Factor I; Male; Middle Aged; Neurosurgical Procedures; Somatostatin; Young Adult

2017
The efficacy of medical treatment in patients with acromegaly in clinical practice.
    Endocrine journal, 2018, Jan-30, Volume: 65, Issue:1

    Topics: Acromegaly; Adenoma; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Female; Follow-Up Studies; Growth Hormone-Secreting Pituitary Adenoma; Hospitals, University; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Neoplasm Grading; Republic of Korea; Retrospective Studies; Somatostatin; Tumor Burden

2018
[Abnormalities of carbohydrate metabolism in acromegaly].
    Medicina clinica, 2013, Nov-16, Volume: 141, Issue:10

    Topics: Acromegaly; Adult; Aged; Blood Glucose; Body Mass Index; Cabergoline; Combined Modality Therapy; Cranial Irradiation; Cross-Sectional Studies; Ergolines; Female; Glucose; Glycated Hemoglobin; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hyperglycemia; Hypophysectomy; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Neoplasms; Retrospective Studies; Somatostatin; Tumor Burden

2013
Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study.
    Clinical endocrinology, 2014, Volume: 81, Issue:6

    Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Drug Therapy, Combination; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Injections, Subcutaneous; Insulin-Like Growth Factor I; Lipodystrophy; Male; Middle Aged; Octreotide; Receptors, Somatotropin; Retrospective Studies; Spain; Treatment Failure; Treatment Outcome

2014
[Contemporary options and perspectives in the treatment of acromegaly].
    Casopis lekaru ceskych, 2014, Volume: 153, Issue:3

    Topics: Acromegaly; Adenoma; Antineoplastic Agents; Cabergoline; Ergolines; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Octreotide; Peptides, Cyclic; Radiosurgery; Receptors, Somatotropin; Somatostatin

2014
Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors.
    European journal of endocrinology, 2015, Volume: 172, Issue:6

    Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Drug Therapy, Combination; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Male; Middle Aged; Remission Induction; Somatostatin; Treatment Outcome; Young Adult

2015
Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR.
    Pituitary, 2011, Volume: 14, Issue:2

    Topics: Acromegaly; Adenoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Delayed-Action Preparations; Drug Resistance, Neoplasm; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Octreotide; Time Factors; Young Adult

2011
Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
    Endocrine journal, 2013, Volume: 60, Issue:4

    Topics: Acromegaly; Adenoma; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Delayed-Action Preparations; Drug Resistance; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Humans; Insulin-Like Growth Factor I; Japan; Male; Middle Aged; Octreotide; Pituitary Gland; Retrospective Studies; Somatostatin; Tumor Burden; Young Adult

2013
Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome.
    Clinical endocrinology, 2007, Volume: 66, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Agents, Hormonal; Body Height; Body Mass Index; Bromocriptine; Cabergoline; Combined Modality Therapy; Ergolines; Female; Growth Hormone; Growth Hormone-Secreting Pituitary Adenoma; Headache; Hormone Antagonists; Humans; Insulin Resistance; Insulin-Like Growth Factor I; Male; Menstruation Disturbances; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Retrospective Studies; Somatostatin; Treatment Outcome

2007
Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
    European journal of endocrinology, 2008, Volume: 158, Issue:5

    Topics: Adult; Antineoplastic Agents; Cabergoline; Dopamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Humans; Ligands; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2; Receptors, Somatostatin; RNA, Messenger; Somatostatin; Tumor Cells, Cultured

2008